RTP Mobile Logo

Friday, December 8, 2017, Atlanta, Georgia, 6:00 PM – 9:00 PM (Eastern Time)

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis (Part 2 of a 2-Part Series)

A Friday Satellite Symposia Series Preceding the 59th ASH Annual Meeting & Exposition

Event Details

Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Event Times:
6:00 PM – 6:30 PM (Eastern Time) — Registration and Dinner Buffet
6:30 PM – 9:00 PM (Eastern Time) — Educational Meeting

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

There is no registration fee for this event. However, preregistration is advised, as seating is limited.

Meletios A Dimopoulos, MD
Chairman, Department of Medical Therapeutics
University of Athens School of Medicine
Athens, Greece

Sagar Lonial, MD
Professor and Executive Vice Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Nikhil C Munshi, MD
Professor of Medicine, Harvard Medical School
Director of Basic and Correlative Science
Associate Director, Jerome Lipper
Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Robert Z Orlowski, MD, PhD
Florence Maude Thomas
Cancer Research Professor
Chair ad interim
Department of Lymphoma and Myeloma
Professor, Department of
Experimental Therapeutics
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida


MODULE 1: Up-Front Management of Multiple Myeloma (MM); Smoldering Myeloma — Dr Lonial

Faculty Presentation Topics

  • Evidence-based selection of induction therapy for patients with normal- and high-risk disease who are eligible and not eligible for transplant 
  • Longer-term follow-up and emerging data with novel front-line triplets (RVD lite, carfilzomib/lenalidomide/dexamethasone [KRd], et cetera)
  • Ongoing evaluation of novel agents (daratumumab, elotuzumab, ixazomib, panobinostat, et cetera) as a component of induction therapy
  • Deciphering smoldering from active MM and indications for treatment versus observation

Sample Questions Contributed by Consulting Oncologists

  • Should adverse cytogenetics influence choice of up-front therapy, including use of transplant, in younger patients with MM?
  • In what situations is it preferable to use KRd as opposed to RVd as up-front treatment? Should any of the novel agents be considered as part of induction therapy at this time?
  • For older patients with MM, are doublets or reduced-dose triplets such as RVd lite preferable as up-front therapy?
  • How do we define high-risk smoldering MM, and is it still appropriate to observe these patients?

MODULE 2: Consolidation and Maintenance Therapy — Dr Orlowski

Faculty Presentation Topics

  • Clinical trial evidence supporting the use of maintenance and consolidation therapy for patients with normal- and high-risk disease
  • Long-term risks associated with the use of extended maintenance therapy with lenalidomide and/or bortezomib
  • Available and emerging research data with ixazomib maintenance; current off-protocol role, if any
  • Impact of minimal residual disease (MRD) status on outcomes in patients with MM; role, if any, of MRD assessment in general oncology practice

Sample Questions Contributed by Consulting Oncologists

  • What approach to maintenance therapy should be taken in a patient with severe motor and sensory neuropathy after 4 cycles of RVd?
  • Would you recommend a combined maintenance approach rather than lenalidomide alone in patients with high-risk cytogenetics? What duration of maintenance therapy would you administer?
  • At this time, is ixazomib a reasonable option in the maintenance setting given its oral route of administration?

MODULE 3: Management of Relapsed or Refractory (R/R) MM — Dr Munshi

Faculty Presentation Topics

  • Impact of prior therapeutic exposure, disease-free interval, cytogenetic status and symptomatology on therapeutic decision-making
  • Optimal selection and sequencing of available agents (eg, carfilzomib, pomalidomide, daratumumab, elotuzumab, ixazomib and panobinostat) for patients with R/R disease
  • Incidence and management of common side effects and rare toxicities associated with these agents
  • Emerging research information and ongoing evaluation of novel combination strategies featuring existing and recently approved therapies

Sample Questions Contributed by Consulting Oncologists

  • What is the optimal treatment approach for a patient who undergoes RVd induction and autologous stem cell transplant but experiences biochemical relapse a year or 2 years into lenalidomide maintenance?
  • What are the optimal dose and schedule of carfilzomib in the R/R setting, and how should intravenous hydration be approached?
  • Given that elotuzumab is approved in combination with lenalidomide and many patients experience disease progression while receiving lenalidomide maintenance, who is the ideal candidate for this agent?
  • When should daratumumab be used, and what should it be combined with? What is the potential clinical utility of the subcutaneous formulation of this drug?

MODULE 4: Novel Strategies Under Investigation for the Treatment of MM — Dr Raje

Faculty Presentation Topics

  • Early efficacy and safety results with BCMA-targeted CAR T cells in MM
  • Ongoing investigation of venetoclax and potential clinical role, particularly in patients with t(11;14)
  • Available data with anti-PD-1/PD-L1 antibodies in MM and implications of trial closures for future research
  • Other promising agents and strategies under investigation

Sample Questions Contributed by Consulting Oncologists

  • What are the mechanistic differences between the CAR T-cell therapy that is being investigated in MM and the platforms that are already available in other hematologic cancers?
  • Is the risk of tumor lysis syndrome with venetoclax in MM the same as it is in chronic lymphocytic leukemia?
  • Will anti-PD-1/PD-L1 antibodies have a role in the treatment of MM? Why were more adverse events reported in patients with MM than have been reported with these agents in most other diseases? 

MODULE 5: Amyloidosis (AL) and Waldenström Macroglobulinemia (WM) — Dr Dimopoulos

Faculty Presentation Topics

  • Evidence-based use of various systemic approaches (chemotherapy, proteasome inhibitors, IMiDs, et cetera) in the up-front treatment of primary AL
  • Emerging data with daratumumab in patients with treatment-refractory AL
  • Use of rituximab alone or in combination with chemotherapy or other targeted therapies (proteasome inhibitors, IMiDs, et cetera) for patients with WM requiring active treatment
  • Efficacy and side-effect profile of ibrutinib in WM; current role in clinical practice

Sample Questions Contributed by Consulting Oncologists

  • How do you manage AL that is confined to a single organ?
  • What is the best up-front treatment for patients with AL and significant neuropathy? What about those with cardiac involvement?
  • What options are available for a patient with relapsed WM and a potential contraindication to ibrutinib such as atrial fibrillation?

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis (AL).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
  • Appreciate the mechanisms of action of, supportive research database with and FDA-endorsed indications for monoclonal antibodies directed at CD38 and SLAMF7, and effectively identify where and how these agents should be integrated into the clinical management of R/R MM.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies to support quality of life and continuation of treatment.
  • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents for the management of primary AL.
  • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for patients with WM requiring active treatment.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and AL, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.


Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

The Atlanta Marriott Marquis hotel is conveniently located within 1 mile of the Georgia World Congress Center, where the ASH Annual Meeting is taking place.

ASH will provide complimentary shuttle service between official housing hotels and the Georgia World Congress Center on Friday, December 8. Service frequency will vary throughout the day between 6:30 AM and 10:30 PM. Look for detailed shuttle bus schedules in your hotel lobby.



Thank you for your interest in our CME program. At this time, online preregistration is closed for this event. Onsite registration will be open starting at 5:45 PM (local time) on Friday, December 8th. If you are interested in attending, please visit our registration desk located outside the Marquis Ballroom B-D (Marquis Level) at the Atlanta Marriott Marquis hotel (265 Peachtree Center Avenue, Atlanta, GA 30303).

If seats become available for the program, we will accept new registrations on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service, and seating will be prioritized for clinicians in practice.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.


This educational session has been approved by ASH as part of the Friday Satellite Symposia educational schedule, and registration for this event is independent of registration for the ASH conference.